Biosimilars represent a critical advancement in modern medicine, offering safe, effective, and more affordable alternatives to existing biologic therapies. In the United States, the development and approval of biosimilars are governed by a robust regulatory framework established under the Biologics Price Competition and Innovation Act (BPCIA) of 2009.
At the heart of the biosimilar pathway is the principle of high similarity. A biosimilar must closely resemble its FDA-approved reference biologic, allowing for only minor differences in components that do not affect clinical outcomes. Importantly, the biosimilar must demonstrate no clinically meaningful differences in terms of safety, purity, and potency compared to the reference product.
The U.S. FDA uses a “totality of evidence” approach to evaluate biosimilars. This includes detailed analytical comparisons, pharmacokinetic and pharmacodynamic data, and, when necessary, clinical studies to confirm comparable performance. The goal is to ensure that biosimilars work just as well in patients as their original counterparts.
Another core principle is consistency in use. Biosimilars must share the same mechanism of action, dosage form, strength, and route of administration as the reference product. Additionally, a biosimilar may earn an interchangeability designation if it can be expected to produce the same results and poses no additional risk when patients switch between the biosimilar and the reference product.
Manufacturing is equally critical. Biosimilars must be produced in facilities that comply with FDA Good Manufacturing Practices (GMP), ensuring the highest standards of quality and safety.
Together, these principles support the safe integration of biosimilars into the U.S. healthcare system, helping to expand access to vital therapies while maintaining rigorous regulatory oversight.

High Similarity to the Reference Product

• In the U.S., a biosimilar must be highly similar to an FDA-licensed reference biologic (approved under section 351(a) of the Public Health Service Act).
• Analytical studies are the cornerstone — focusing on structural and functional characterization using advanced technologies such as mass spectrometry, bioassays, and chromatography.
•  Minor differences in clinically inactive components (e.g., stabilizers or excipients) are allowed, but must be justified scientifically.

No Clinically Meaningful Differences

The biosimilar must not differ from the reference product in any way that impacts:

• Safety
• Purity
• Potency

To confirm this, biosimilar sponsors typically provide:

• Pharmacokinetic (PK) and Pharmacodynamic (PD) comparison data
• Immunogenicity profiles
• Limited clinical data where necessary
• FDA emphasizes totality of evidence rather than large, stand-alone clinical trials, in contrast to the originator’s approval process.

Totality of Evidence Approach

• The FDA evaluates biosimilarity through a stepwise, science-based process, assessing:
• Analytical similarity (most critical)
• Animal toxicology (if required)
• Clinical PK/PD studies
• Immunogenicity testing
• Comparative clinical trials (when needed)
• Each layer of evidence must reinforce the conclusion that the biosimilar behaves like the reference product in the human body.

Same Route, Dosage Form, and Strength

• The biosimilar must use the same route of administration (e.g., intravenous, subcutaneous), dosage form (e.g., injection, infusion), and strength as the reference product.
• This ensures consistency in how the drug is delivered, absorbed, and acts in the body.
• These factors support labeling consistency and interchangeability evaluation.

Interchangeability Designation (Optional but Critical)

• To be designated as interchangeable, a biosimilar must:
• Meet all biosimilarity standards, plus
• Show it can be substituted at the pharmacy level without prescriber intervention (subject to state law)
• Provide data from switching studies, demonstrating that alternating between the biosimilar and reference product does not increase risk of adverse effects or reduce efficacy.
• Interchangeable biosimilars are especially important in the retail and pharmacy settings and are a key factor in enhancing biosimilar uptake in the U.S.

Robust Manufacturing and FDA Oversight

• All biosimilar manufacturing sites must adhere to Current Good Manufacturing Practices (CGMPs).
• The FDA inspects facilities as part of the 351(k) approval process to ensure consistent product quality and batch reliability.
• Facilities must also support process control, scalability, and post-market pharmacovigilance.
• Additionally, U.S. regulations require:
• Traceability and labeling clarity
• Product-specific pharmacovigilance plans
• Post-approval monitoring and safety reporting aligned with reference biologics